Diagnosis and Management of Chronic Obstructive Pulmonary Disease (COPD)

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".

Deadline for manuscript submissions: 31 August 2024 | Viewed by 1157

Special Issue Editors

E-Mail Website
Guest Editor

E-Mail Website
Guest Editor
Medicine-Pulmonary, Critical Care and Sleep Medicine Baylor College of Medicine, Houston, TX, USA
Interests: asthma; chronic obstructive pulmonary disease; critical care ultrasonography; thromboembolic diseases
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

COPD is a chronic inflammatory disorder of the airways characterized by irreversible or partially reversible airflow limitation, and is a major cause of morbidity as well as mortality across the globe. Around 300 million people suffer from COPD across the globe. Several risk factors as well as several phenotypes and endotypes have been identified. GOLD guidelines form the cornerstone for the management of COPD, especially for primary care practitioners. However, there are several unanswered questions. For example, there is little information on why a significant proportion of the population exposed to the same risk factors are protected from developing COPD. Are there any biomarkers that can potentially identify future COPD subjects when there is no lung damage yet? One key biomarker is CC16; what is the value of CC16 in such a scenario? What are the future treatment options that can help to arrest disease progression? What is the role of biologics in the management of COPD and asthma–COPD overlap? How well have we understood COPD genetics, and have we obtained valuable information that could be of clinical value for the routine management of COPD patients? What are the lessons that we have learnt from the “omics” platforms (proteomics, metabolomics, genomics, metagenomics, and epigenomics) that can be translated from bench to bedside? What is the role of AI in the diagnosis and management of COPD? What public health initiatives are necessary to handle COPD well in LMIC countries where there is no access to advanced testing and treatment? How can a primary care practitioner diagnose COPD when there is no access to spirometry? What is the impact of ambient air pollution and indoor air pollution on the prevalence of COPD across the globe?

We have undoubtedly made great progress in the last few decades, but we still have a long way to go to reduce this huge public health problem, which is indeed reaching epidemic proportions. Remember, the burden of COPD seen currently is due to exposures 2–3 decades ago (smoking, biomass use, air pollution, and occupations). Since then, the number of people exposed to these risk factors have only increased, and the impact of the current burden of risk factors will only be realised in the next few decades.

It is our great pleasure to invite you to submit articles on the topic of COPD. This Special Issue, entitled “Global burden, pathophysiology, diagnosis, treatment, and novel therapeutics in COPD”, will cover all aspects of the epidemiology, risk factors, pathophysiologic mechanisms, biomarkers, clinical investigations, treatment, prognosis, and natural history of COPD. I believe this would present an excellent opportunity to publish your hard work. Submissions, such as original articles or narrative/systematic reviews, are welcome. Please note that we do not accept case/brief reports.

Topics include, but are not limited to, the following:

  • Burden of COPD (national, subnational, or global estimates);
  • Risk factors;
  • Pathophysiologic mechanisms and pathology in COPD;
  • Genomics in COPD;
  • Metabolomics in COPD;
  • Epigenetics in COPD;
  • Metagenomics, gut microbiome, and lung microbiome in COPD;
  • Biomarkers in COPD;
  • Airway remodelling in COPD;
  • Phenotypes and endotypes in COPD;
  • Frequent exacerbators and disease progression in COPD;
  • COPD comorbidities;
  • Patient-reported outcomes;
  • Health status or health-related quality of life;
  • COPD and COVID-19 interactions;
  • Artificial intelligence in COPD diagnosis.

Prof. Dr. Padukudru Anand Mahesh
Dr. Muhammad Adrish
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


11 pages, 866 KiB  
Comparison of Disease Severity Classifications of Chronic Obstructive Pulmonary Disease: GOLD vs. STAR in Clinical Practice
by Koichi Nishimura, Masaaki Kusunose, Ayumi Shibayama and Kazuhito Nakayasu
Diagnostics 2024, 14(6), 646; https://doi.org/10.3390/diagnostics14060646 - 19 Mar 2024
Viewed by 924
Background: In chronic obstructive pulmonary disease (COPD), there are two known classifications for assessing what is called disease severity. One is the Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification, which is based on the post-bronchodilator value of FEV1 (% reference). [...] Read more.
Background: In chronic obstructive pulmonary disease (COPD), there are two known classifications for assessing what is called disease severity. One is the Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification, which is based on the post-bronchodilator value of FEV1 (% reference). The other is the STaging of Airflow obstruction by Ratio (STAR), with four grades of severity in subjects with an FEV1/FVC ratio <0.70: STAR 1 ≥0.60 to <0.70, STAR 2 ≥0.50 to <0.60, STAR 3 ≥0.40 to <0.50, and STAR 4 <0.40. Purpose: The aim of this study was to compare the staging of COPD using the GOLD and STAR classifications in clinical practice. Methods: We reanalyzed data from our outpatient cohort study, which included 141 participants with COPD from 2015 to 2023. We compared mortality and COPD-specific health status between the GOLD 1 to 4 groups and the STAR 1 to 4 groups. Results: By simple calculation, GOLD and STAR severity classes coincided in 75 participants (53.2%). The weighted Bangdiwala B value with linear weights was 0.775. The participants were observed for up to 95 months, with a median of 54 months. Death was confirmed in 29 participants (20.5%). In univariate Cox proportional hazards analyses, there was a significant difference in mortality between the GOLD 1 and GOLD 3 + 4 groups, with the GOLD 1 group used as the reference [hazard ratio 4.222 (95% CI 1.298–13.733), p = 0.017]. However, there was no statistically significant predictive relationship between STAR 1 and STAR 2, or between STAR 1 and STAR 3 + 4. St. George’s Respiratory Questionnaire (SGRQ) Total and COPD Assessment Test (CAT) scores were significantly different between all GOLD groups, except for the CAT score between GOLD 1 and GOLD 2. The SGRQ Total and CAT scores were significantly different between STAR 1 and STAR 3 + 4, but not between STAR 1 and STAR 2. Conclusion: From the perspective of all-cause mortality and COPD-specific health status, the GOLD classification is more discriminative than STAR. Full article
Show Figures

Figure 1

Back to TopTop